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Edited by Robert BaroukiAbstract The treatment of human ﬁbroblasts with diﬀerent
tocopherols in the presence of retinol caused an increase in
cytoplasmic retinoic acid binding protein II (CRABP-II) mRNA
and protein. The possibility of an involvement of protein kinase
C (PKC) in the response to tocopherols was supported by the
results obtained with the PKC-speciﬁc inhibitors, calphostin C
and bisindolylmaleimide I. The eﬀect of a-tocopherol was
prevented by okadaic acid, suggesting that a protein phosphatase
is responsible for PKC dephosphorylation produced by the
presence of tocopherols. The results shown support the hypoth-
esis that phosphorylation/dephosphorylation of RXRa via PKC
may be involved in the regulation of CRABP-II gene expression.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Cytoplasmic retinoic acid binding protein II;
Fibroblast; Protein kinase C; Protein phosphatase; Retinoid X
receptor a; Vitamin E1. Introduction
Retinoids (vitamin A and its derivatives) are essential reg-
ulators of epithelial cell growth and cellular diﬀerentiation in
both fetal and adult tissues. Skin is a major target of retinoids
both in normal and pathological states [1].
Diﬀerent intracellular retinoid-binding proteins have been
identiﬁed. Retinol and retinoic acid are bound to speciﬁc cel-
lular binding proteins. These proteins are involved in the
regulation of the intracellular concentration of these retinoids
by acting as shuttle proteins, facilitating their transport, or as
storage proteins, maintaining constant levels of free retinol and
retinoic acid [2].
Two cytoplasmic retinoic acid binding proteins, CRABP-I
and CRABP-II, have been characterized. CRABP-I is ex-
pressed almost ubiquitously, whereas CRABP-II expression is
localized almost exclusively in skin, basically in keratinocytes
and ﬁbroblasts [3]. Furthermore, the expression of CRABP-II
is upregulated by retinol and retinoic acid in human skin as* Corresponding author. Fax: +34-963544917.
E-mail address: mirallev@uv.es (V.J. Miralles).
Abbreviations: CRABP, cytoplasmic retinoic acid binding protein;
RARE, retinoic acid response element; RAR, retinoic acid receptor;
RXR, retinoid X receptor; PKC, protein kinase C; RT-PCR, reverse
transcription-polymerase chain reaction; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase
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mRNA expression was not induced by retinoic acid and was
undetectable in normal human skin by Northern blot analysis
[4]. The human CRABP-II gene promoter contains two cis-
acting DNA retinoic acid response elements (RAREs), which
mediate the induction of CRABP-II by the ligand-inducible
trans regulators retinoic acid receptors (RARs a, b and c) and
retinoid X receptors (RXRs a, b and c), which bind much
more eﬃciently to RAREs as RAR–RXR heterodimers than
homodimers [5]. In human skin, the predominant RAR tran-
script is RARc and the predominant RXR transcript is RXRa
[6] and CRABP-II is known to be controlled by RARc/RXRa
heterodimer [7].
Vitamin E is considered as an important antioxidant
molecule which prevents diseases associated with oxidative
stress like cardiovascular disease, chronic inﬂammation,
cancer and neurologic disorders. In addition, novel functions
of vitamin E have been discovered such as inhibition of cell
proliferation [8,9] and gene expression [10–13], and upregu-
lation of a-tropomyosin [14] and a-tocopherol transfer pro-
tein [15]. The link between some of these functions of
vitamin E appears to be protein kinase C (PKC) [8,9,13,16].
PKC belongs to a family of related Ser/Thr kinases with a
key role in the transduction of signals mediated by cytokines,
growth factors, and hormones. PKC is a family of several
isoenzymes and it was found that only PKCa was inhibited
by a-tocopherol [17]. Inhibition of PKCa occurs because a-
tocopherol induces the activation of protein phosphatase 2A
which causes dephosphorylation and inactivation of PKCa
[17].
It has been also demonstrated that PKC is able to phos-
phorylate RAR in vitro and in vivo [18,19]. This phosphory-
lation decreases the ability of human RARa to dimerize with
RXRa, aﬀecting the transcriptional activity modulated by the
heterodimer RAR–RXR [18]. Protein phosphatases 1 and 2A
are also involved in the transcriptional and DNA binding ac-
tivities of RAR–RXR heterodimers [20,21]. Phosphorylation
of RXRa by mitogen-activated protein kinase (MAPK) also
impairs the transcriptional activity of RAR/RXR [22,23] and
VDR/RXR [24] heterodimers.
In this study, we show that tocopherol (a, c and d) treatment
of human cultured ﬁbroblasts in the presence of retinol leads
to an increase in CRABP-II mRNA and protein expression.
This expression appears to be regulated by PKC because the
treatment of ﬁbroblasts with speciﬁc PKC or protein phos-
phatase inhibitors aﬀects CRABP-II expression. Western blot
analysis with anti-phosphoserine antibody showed that RXRablished by Elsevier B.V. All rights reserved.
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a-tocopherol or PKC inhibitors decreased their phosphoryla-
tion levels. The results are consistent with a model in which
tocopherols cause inactivation of PKC with a concomitant
dephosphorylation of RXRa and an increase in the amounts
of mRNA and protein for CRABP-II.Fig. 1. Eﬀect of diﬀerent tocopherols on CRABP-II mRNA. Total
RNA was isolated from untreated ﬁbroblasts (C) or ﬁbroblasts treated
with retinol (ROH), retinol plus 100 lM of a-tocopherol (ROH+ a-
toc), retinol plus 100 lM c-tocopherol (ROH+ c-toc) or retinol plus
100 lM d-tocopherol (ROH+ d-toc) for 14 h and ampliﬁed by RT-
PCR using speciﬁc primers for CRABP-II and GAPDH as described in
Section 2. One ﬁfth of the total ampliﬁed product was then analyzed
on 1.5% agarose gel stained with ethidium bromide. The graphs show
the ratios of CRABP-II to GAPDH for each experimental condition
and represent the means (S.D.) of three independent experiments.2. Materials and methods
2.1. Materials
(+)-a-Tocopherol, (+)-c-tocopherol, (+)-d-tocopherol, all trans-reti-
nol, calphostin C and okadaic acid were all purchased from Sigma (St.
Louis, MO). Bisindolylmaleimide I hydrochloride and monoclonal
antibody against phosphoserine (clone16B4) were purchased from
Calbiochem–Novabiochem GmbH (Darmstadt, Germany). Dynabe-
ads M-280 (sheep anti-rabbit IgG) were purchased from Dynal
Biotech. (Oslo, Norway). CRABP-II monoclonal antibody was a
generous gift of Dr. Cecile Rochette-Egly, b-actin goat polyclonal,
RARc rabbit polyclonal and RXRa rabbit polyclonal antibodies were
purchased from St. Cruz Biotechnology (St. Cruz, CA). All other
chemicals used were of the purest grade commercially available.
(+)-a-Tocopherol, (+)-c-tocopherol, (+)-d-tocopherol and all trans-
retinol were prepared in ethanol with 0.01% butylated hidroxytoluene,
1000 times more concentrated than the ﬁnal concentration in the cul-
ture medium. Calphostin C, bisindolylmaleimide I and okadaic acid
were prepared in DMSO, 1000 times more concentrated than the ﬁnal
concentration in the culture medium. The ﬁnal concentration of eth-
anol and DMSO in the culture medium was 0.1% (v/v), this concen-
tration had no detectable eﬀect by itself. All experiments were
performed using freshly dissolved material. All the experiments pre-
sented in this study were repeated at least three separate times with
similar results.
2.2. Cell culture
Human dermal ﬁbroblasts were obtained from juvenile foreskins and
grown as described [25]. Fibroblasts between passage number 4 and 12
were used throughout all the experiments. After conﬂuence was
reached, the serum content of the medium was reduced to 0.5% and the
ﬁbroblasts were treated with the test compounds plus 1 lM retinol.
2.3. Isolation of total RNA and analysis of mRNA expression by
RT-PCR
Total RNA isolation and reverse transcription reactions were done
as described [25]. The PCR analysis for CRABP-II and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was performed using Biotools
DNA polymerase gel-form from B & M Labs, S.A. (Madrid, Spain)
following the instructions of the manufacturer. The conditions for each
PCR were determined in preliminary experiments and optimized for
each set of primers. The speciﬁc primers (50 to 30) were for CRABP-II:
ATGCCCAACTTCTCTGGCAA and CGTCATGGTCAGGAT-
CAGTT and for GAPDH: TCACCACCATGGAGAAGGCT and
AAGGCCATGCCAGTGAGCTT. The ampliﬁcation conditions were
1 cycle at 85 C for 2 min and 1 cycle at 94 C for 2 min. Then, for
CRABP-II 25 cycles of denaturation (94 C for 30 s), annealing (59 C
for 30 s) and extension (70 C for 1 min) with a ﬁnal extension of 70 C
for 1 min and for GAPDH 25 cycles of denaturation (94 C for 30 s),
annealing (53 C for 30 s) and extension (70 C for 1 min) with a ﬁnal
extension of 70 C for 1 min. The resulting PCR products were sep-
arated by electrophoresis in a 1.5% agarose gel in TBE and stained
with ethidium bromide. The expected sizes for the PCR products were
as follows: CRABP-II, 375 bp and GAPDH, 390 bp. The intensity of
the bands was measured by densitometry using the GeneGenius system
and the GeneTools analysis software (Syngene, Cambridge, UK).
2.4. Immunoprecipitation and Western blot analysis
Serine phosphorylation of RXRa or RARc from human dermal ﬁ-
broblasts was determined by immunoprecipitating RXRa or RARc,
respectively, from 175 lg of total protein from whole cell extracts
through overnight incubation at 4 C with 5 lg of a polyclonal anti-
RXRa or anti-RARc antibody bound to Dynabeads M-280 following
the instructions of the manufacturer. Immunoprecipitates were then
washed three times with PBS containing 0.25 mM phenylmethylsulfonyl ﬂuoride and ﬁnally boiled for 5 min in electrophoresis sample
buﬀer. Western blot analysis was done as described [25] except that the
membranes were blocked in 5% bovine serum albumin instead of 3%
non-fat milk in TBST to avoid milk phosphoproteins.
2.5. Transfection and luciferase assays
Fibroblast cells were cultured in 6-well plates and transfected with
the luciferase reporter plasmids (2 lg/plate), pGL3-RARP-Luc, con-
taining RARE from position )55 to )35 of the human RAR-b pro-
moter or pDR5-TK-Luc, containing direct repeats of AGGTC
separated by ﬁve nucleotides in the context of heterologous TK pro-
moter [23], both kindly provided by Dr. J.M. Kurie. Transfections
were performed using lipofectamine reagent (Invitrogen, Life Tech-
nologies, Inc) as described [26]. Transfected cells were washed twice
with Opti-MEM (Gibco, Life Technologies, Inc), incubated in 10%
FCS containing medium for 12 h and then cultured overnight in me-
dium containing 0.5% serum and treated with 1 lM retinol alone or
with 1 lM retinol plus a-tocopherol, calphostin C, bisindolylmalei-
mide I or okadaic acid plus a-tocopherol. Luciferase activity of each
cell lysate was measured using the luciferase assay system, as described
by the manufacturer (Promega; Madison, WI).3. Results and discussion
We reported [25] that the treatment of human dermal ﬁ-
broblasts with retinoic acid or retinol produced an increase of
CRABP-II mRNA compared to controls as expected from
previous results [27]. Interestingly, in our work [25], the
treatment of ﬁbroblasts with retinol together with vitamin E
produced a major increase of CRABP-II mRNA compared to
the treatment of ﬁbroblasts with retinoic acid or retinol alone.
In light of these results, we decided to study the eﬀect of
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(c-) and trimethyl- (a) tocols) on CRABP-II mRNA and
protein expression.
Human dermal ﬁbroblasts were incubated with 100 lM a-,
c- or d-tocopherol during 14 h, in the presence of retinol. Total
RNA was isolated as described in Section 2 and reverse tran-
scription-polymerase chain reaction (RT-PCR) analysis of
equal amounts of RNA was done. Reverse transcription and
ampliﬁcation conditions were established previously to permit
the comparison of the mRNA levels in the diﬀerent experi-
mental conditions. The results of representative RT-PCR ex-
periments involving treatment of ﬁbroblasts with the diﬀerent
tocopherols (a, c or d) are shown in Fig. 1. As observed, the
three tocopherol isomers used induced CRABP-II mRNA. a-
Tocopherol produced the greatest response (3.4-fold), followed
by d-tocopherol (2.5-fold) and c-tocopherol (2.2-fold).
Western blot analysis with anti-CRABP-II antibody showed
that treatment of human dermal ﬁbroblasts for 24 h with 100
lM a-tocopherol plus retinol (Fig. 2A, lane 2), 100 lM c-to-
copherol plus retinol (Fig. 2A, lane 3) and 100 lM d-tocoph-
erol plus retinol (Fig. 2A, lane 4) resulted in an increase of
CRABP-II protein levels compared with the control (Fig. 2A,
lane 1), as was observed at the mRNA level (Fig. 1).
Because PKC inhibition by diﬀerent tocopherol isomers has
been reported [16], it was interesting to establish whether the
observed increase in CRABP-II expression was due to a to-
copherol-mediated PKC inhibition. Calphostin C, a selective
PKC enzyme inhibitor, provoked an increase in CRABP-II
protein levels (Fig. 2A, lane 5), similar to that observed with
the diﬀerent tocopherol isomers (compare lane 5 with lanesFig. 2. Eﬀect of tocopherols, calphostin C and okadaic acid plus a-tocophero
of protein (5 lg) derived from ﬁbroblasts treated for 24 h. with retinol alon
(lane 2), 100 lM c-tocopherol plus retinol (lane 3), 100 lM d-tocopherol plus
tocopherol plus retinol and 2 nM okadaic acid (lane 6) were probed with anti
an antibody speciﬁc for b-actin. (B) Total RNA was isolated from untreated
retinol (a-toc) or 100 lM a-tocopherol plus retinol and 2 nM okadaic acid (O
for CRABP-II and GAPDH as described in Section 2. One ﬁfth of the total
ethidium bromide. The graphs show the ratios of CRABP-II to GAPDH for
independent experiments.2–4). It has also been demonstrated that a-tocopherol induces
the activation of protein phosphatase 2A resulting in the de-
phosphorylation and consequent inactivation of PKCa [17]. In
our experimental model, the possible inhibitory eﬀect of a-
tocopherol on PKC was reversed by okadaic acid, a potent
inhibitor of protein phosphatases 1 and 2A [28]. In Fig. 2A
(lane 6), we observed that ﬁbroblast treatment with a-to-
copherol plus retinol and 2 nM okadaic acid reduced CRABP-
II protein almost to control levels (lane 1). Similar results were
obtained by RT-PCR analysis (Fig. 2B). Because the observed
eﬀect was produced with 2 nM okadaic acid and the IC50 for
this inhibitor is 10–15 nM for protein phosphatase 1 and 0.1
nM for protein phosphatase 2A, we can assume that the pro-
tein phosphatase 2A is the phosphatase responsible for the
observed PKC inactivation.
Under the same culture conditions, luciferase expression
increased after treatment of ﬁbroblasts with 1 lM retinol as
expected. Moreover, the treatment of ﬁbroblasts with a-to-
copherol, calphostin C or bisindolylmaleimide I together with
1 lM retinol provoked the maximum eﬀect (Fig. 3). Thus, our
results overall consistently indicate that CRABP-II expression
was increased through RARE by a-tocopherol or PKC in-
hibitors in the presence of retinol.
Phosphorylation events can inactivate nuclear receptors (for
a review, see [29,30]). In the case of RARa, inhibition of the
transcriptional activity occurs by phosphorylation of residues
located within the DNA-binding domain by PKC [18]. Since
CRABP II gene expression is regulated by the binding of
RARc–RXRa heterodimer to their RAREs [7], we have in-
vestigated if the eﬀect observed in CRABP II expression byl on CRABP-II expression. (A) Western blot analysis of equal amounts
e (lane 1) or ﬁbroblasts treated with 100 lM a-tocopherol plus retinol
retinol (lane 4), 100 nM calphostin C plus retinol (lane 5) or 100 lM a-
-CRABP-II as described in Section 2. The same blot was reprobed with
ﬁbroblasts (C) or ﬁbroblasts treated with 100 lM of a-tocopherol plus
k.A. + a-toc) for 14 h and ampliﬁed by RT-PCR using speciﬁc primers
ampliﬁed product was then analyzed on 1.5% agarose gel stained with
each experimental condition and represent the means (S.D.) of three
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Fig. 3. Luciferase activity in human dermal ﬁbroblasts transiently
transfected with reporter plasmids containing RAREs. Luciferase as-
says were performed on ﬁbroblast cells transiently transfected with
pGL3-RARP-Luc or pDR5-TK-Luc as described in Section 2.
Transfected cells were treated with 1 lM retinol (ROH), 100 lM a-
tocopherol plus 1 lM retinol (a-toc), 100 nM calphostin C plus 1 lM
retinol (calph. C), 50 nM bisindolylmaleimide I plus 1 lM retinol
(BDM I), 100 lM a-tocopherol plus 1 lM retinol and 2 nM okadaic
acid (Ok.A.+ a-toc) or without any treatment (C). Data presented in
the ﬁgure represent the means (S.D.) of three independent experi-
ments using 20 lg of cell extract.
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of RARc and/or RXRa.
Western blot analysis of whole cell extracts immunoprecip-
itated with an antibody against RXRa showed that the
amount of RXRa protein did not change in any of the diﬀerent
incubation conditions of the ﬁbroblasts (Fig. 4A, upper panel).
However, when the same blot was probed with a monoclonal
antiphosphoserine antibody, we observed that the treatment of
dermal ﬁbroblast with a-tocopherol plus retinol (Fig. 4A,
lower panel, lane 2), calphostin C plus retinol (lane 3) and
bisindolylmaleimide I plus retinol (lane 4) decreased theFig. 4. Phosphorylation of RXR and RAR on serine residues in human derm
ﬁbroblasts treated for 24 h. with retinol (lane 1), 100 lM a-tocopherol plu
bisindolylmaleimide I plus retinol (lane 4), 100 lM a-tocopherol plus retino
immunoprecipitated with an anti-RXR or anti-RAR antibody as described in
speciﬁc antibody to RXR, RAR or phosphoserine. The lanes indicated as (
without whole cell extract, respectively. The graphs show the ratios of RXRa
for each experimental condition and represent the means (S.D.) of three inphosphorylation levels of RXRa compared with ﬁbroblasts
treated with retinol alone (lane 1). The treatment of dermal
ﬁbroblasts with a-tocopherol plus retinol and okadaic acid
(lane 5) increased the phosphorylation of RXRa almost to half
of control level. Curiously, the phosphorylation level in serine
residues of RXRa in untreated ﬁbroblast (lane 6) is less than
that observed in the ﬁbroblast treated with retinol alone (lane
1), suggesting that ligand binding to RXRa provokes struc-
tural changes in RXRa which facilitate the action of PKC.
This observation is in agreement with a previous report [18].
These results suggest that the eﬀect of PKC on RXRa involved
the modulation of the phosphorylation state rather than af-
fecting the levels of RXRa protein. Western blot analysis using
the same antiphosphoserine antibody did not indicate any
diﬀerences in RARc phosphorylation in human dermal ﬁbro-
blasts (see Fig. 4B). Our results are in agreement with those of
Delmotte et al. [18] where they showed that PKCa and c were
able to phosphorylate RARa in vitro and this phosphoryla-
tion, which occurs on a single serine residue, inhibits the for-
mation of RAR–RXR heterodimers and consequently their
transcriptional activity. Furthermore, our results are consis-
tent with a model in which tocopherol induces the activation of
protein phosphatase 2A, which dephosphorylates and inacti-
vates PKC, which in turn leads to the dephosphorylation of
RXRa, increasing the ability of this factor to heterodimerize
with RARc and, in the presence of the ligand, RARc–RXRa
heterodimers activate the expression of CRABP-II.
Other nuclear receptors in addition to RAR and RXR have
been described as substrates of PKC: thyroid hormone re-
ceptor (T3R) [31] and vitamin D3 receptor (VDR) [32]. In the
case of VDR, PKC activation inhibited VDR-mediated tran-
scription by a mechanism involving phosphorylation of serine
51 located in the DNA binding domain of VDR.
Besides PKC, other kinases have been implicated in the
phosphorylation of nuclear receptors including RXR [29,30].al ﬁbroblasts. Whole cell extracts were prepared from human dermal
s retinol (lane 2), 100 nM calphostin C plus retinol (lane 3), 50 nM
l and 2 nM okadaic acid (lane 5) or without any treatment (lane 6);
Section 2, followed by SDS–PAGE andWestern blotting analysis using
–A) and (–E) correspond to immunoprecipitate without antibody and
phosphorylated on serine residues to total RXRa immunoprecipitated
dependent experiments.
244 A. Gimeno et al. / FEBS Letters 569 (2004) 240–244Indeed, phosphorylation of RXRa mediated by MAPK im-
pairs the transcripitional activity of RAR/RXR [22,23] and
VDR/RXR [24] heterodimers, suggestting that PKC, as an
activator of the MAPK pathway [33,34], might participate,
indirectly, in the control of the transcriptional activity of RXR
and other nuclear receptors.
Recently, it has been shown that a-, c- and d-tocopherol are
able to activate gene expression via the pregnane X receptor
(PXR). This nuclear receptor acts by binding to the direct
repeat response element DR3 as a PXR–RXR heterodimer,
regulating the expression of diﬀerent drug metabolizing en-
zymes [35].
In summary, we have shown a direct transcriptional gene
activation by tocopherols via PKC inhibition and mediated by
RXRa.
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